Physician profile
Samir Melki
NPI 1407838295
$8,447.20
in general payments reported to CMS, 2019-2025
27 companies · $2,993 in 2025
The $2,993 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $2,072 · 2021: $1,189 · 2022: $277 · 2023: $598 · 2024: $771 · 2025: $2,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236 · Consulting Fee: $2,100 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.29 |
| Consulting Fee | $2,100.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,100.00 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $2,025.54 | 2019-2020 | |
| Alcon Vision LLC | $1,347.99 | 2019-2025 | Wavelight Ex500 Excimer Laser, Wavelight Refractive Suite, Ngenuity |
| Allergan, INC. | $1,058.46 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $258.37 | 2024 | |
| Novartis Pharmaceuticals Corporation | $240.73 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $209.11 | 2024-2025 | Xdemvy |
| Rxsight INC | $208.05 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $170.53 | 2019-2025 | Oxervate |
| Abbvie INC. | $152.22 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $143.83 | 2019-2025 | |
| Oyster Point Pharma, INC. | $88.96 | 2022-2025 | Ryzumvi, Tyrvaya |
| Amgen INC. | $71.98 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $63.59 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Harrow Eye, LLC | $49.55 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $40.57 | 2023-2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Ocular Therapeutix, INC. | $34.67 | 2023-2025 | Dextenza |
| Ani Pharmaceuticals, INC. | $30.36 | 2025 | Purified Cortrophin Gel |
| Johnson & Johnson Vision Care, INC. | $27.70 | 2025 | |
| Sight Sciences, INC. | $23.87 | 2019 | |
| Horizon Therapeutics Plc | $23.45 | 2023 | Tepezza |
| Lkc Technologies, INC. | $21.04 | 2025 | |
| New World Medical,INC. | $17.65 | 2022 | |
| Thea Pharma INC. | $14.58 | 2025 | Iyuzeh |
| Omeros Corporation | $12.47 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Melki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.